July 15th 2025
Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
ICU Admission Reduces Survival, Augments Costs Among Patients With AML
Addressing the Psychosocial Needs in Older Breast Cancer Patients
Combining IORT With Chemotherapy Improves Survival in Pancreatic Cancer